0XOD Stock Chart & Stats
$41.04
-$0.69(-1.68%)
At close: 4:00 PM EDT
$41.04
-$0.69(-1.68%)
Day’s Range― - ―
52-Week Range$15.92 - $48.10
Previous CloseN/A
Volume273.00
Average Volume (3M)698.00
Market Cap
$1.86B
Enterprise Value$1.94K
Total Cash (Recent Filing)$107.97M
Total Debt (Recent Filing)$196.13M
Price to Earnings (P/E)―
Beta1.10
Next Earnings
Nov 05, 2026EPS Estimate
0.1Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.98
Shares Outstanding48,721,703
10 Day Avg. Volume527
30 Day Avg. Volume698
Financial Highlights & Ratios
PEG Ratio-0.94
Price to Book (P/B)-10.68
Price to Sales (P/S)10.26
P/FCF Ratio-6.92
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$57.33Price Target Upside39.70% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)-0.71
Revenue Forecast (FY)$276.49M
Bulls Say, Bears Say
Bulls Say
High Gross Margins & Revenue GrowthConsistently high gross margins (~88–90%) on growing TTM revenue (~$188.7M) indicate robust product-level economics. Durable unit profitability supports scalable revenue growth, funds reinvestment in commercialization and R&D, and improves the odds of reaching company-level profitability if operating spends normalize.
ZUSDURI Commercial TractionRapid commercial adoption—$50.4M Q2 revenue and 73% QoQ growth—demonstrates product-market fit and an expanding prescriber base. Increasing activated accounts, repeat prescribers and hospital/community uptake indicate durable demand and a sustainable new revenue stream that diversifies reliance on legacy products.
Durable Clinical Data And IP ProtectionLong-term Phase III durability (64.5% disease-free at 36 months) plus patent allowance and a Teva settlement strengthen clinical credibility and extend exclusivity. This combination builds a durable competitive moat, reduces near-term generic risk, and supports long-term commercial returns for core products and related pipeline assets.
Bears Say
Negative Equity & Rising LeverageNegative shareholder equity (~-132M) with rising debt (~196M) constrains financial flexibility and heightens refinancing risk. Persistent losses undermine the equity base, limit borrowing capacity, and increase the chance that future funding needs force dilutive equity issuance or restrictive debt terms, impairing strategic optionality.
Sustained Negative Operating And Free Cash FlowPersistent operating cash burn (-$158.9M TTM) and negative FCF (-$159.1M) show the business currently consumes cash to fund growth. Ongoing deficits necessitate external financing, which increases dilution or leverage and constrains self-funded R&D and commercial expansion until the company achieves sustained positive cash generation.
High Opex And Early Adoption VariabilityManagement's higher opex guidance reflects accelerated investment to support ZUSDURI, yet no full-year ZUSDURI guidance signals demand uncertainty. Elevated spend plus quarter-to-quarter adoption variability increases the risk that profitability and cash-flow targets slip if adoption or conversion rates slow versus assumptions.
Urogen Pharma News
0XOD FAQ
What was Urogen Pharma’s price range in the past 12 months?
Urogen Pharma lowest share price was $15.92 and its highest was $48.10 in the past 12 months.
What is Urogen Pharma’s market cap?
Urogen Pharma’s market cap is $1.86B.
When is Urogen Pharma’s upcoming earnings report date?
Urogen Pharma’s upcoming earnings report date is Nov 05, 2026 which is in 89 days.
How were Urogen Pharma’s earnings last quarter?
Urogen Pharma released its earnings results on Aug 05, 2026. The company reported -$0.28 earnings per share for the quarter, missing the consensus estimate of -$0.265 by -$0.015.
Is Urogen Pharma overvalued?
According to Wall Street analysts Urogen Pharma’s price is currently Undervalued.
Does Urogen Pharma pay dividends?
Urogen Pharma does not currently pay dividends.
What is Urogen Pharma’s EPS estimate?
Urogen Pharma’s EPS estimate is 0.1.
How many shares outstanding does Urogen Pharma have?
Urogen Pharma has 48,721,703 shares outstanding.
What happened to Urogen Pharma’s price movement after its last earnings report?
Urogen Pharma reported an EPS of -$0.28 in its last earnings report, missing expectations of -$0.265. Following the earnings report the stock price went up 15.824%.
Which hedge fund is a major shareholder of Urogen Pharma?
Currently, no hedge funds are holding shares in GB:0XOD
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Urogen Pharma Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$57.33 (39.70% Upside)
$57.33 (39.70% Upside)
Blogger Sentiment
Bullish
GB:0XOD Sentiment 75%
Sector Average ―
Sector Average ―
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
127.61%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
2.45%
Trailing 12-Months
Company Description
Urogen Pharma
UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology; Mitomycin a generic drug used off-label as an adjuvant chemotherapy for the treatment of low-grade NMIBC after trans-urethral resection of bladder tumor; Zusduri, a sustained-release formulation of mitomycin for the treatment of non-muscle invasive bladder cancer (NMIBC); and Jelmyto for pyelocalyceal solutions. The company’s lead product candidates are UGN-103, which is in phase 3 of clinical trial for intravesical solution; and UGN-104 that is in phase 3 of clinical trial for pyelocalyceal solution designed for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial cancer and low-grade intermediate risk NMIBC. It is also developing UGN-301, UGN-301+UGN 201, and UGN-301+gemcitabine that are in phase 1 of clinical trial for the treatment of high-grade NMIBC. The company has license agreement with Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; and licensing and supply agreement with medac Gesellschaft für klinische Spezialpräparate m.b.H. to develop UGN-103 and UGN-104. UroGen Pharma Ltd. was incorporated in 2004 and is headquartered in Princeton, New Jersey.
0XOD Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call communicated strong positive momentum driven by the ZUSDURI launch (Q2 ZUSDURI revenue of $50.4M, rapid growth in activated accounts and prescribers, durable Phase III durability data, pipeline progress, favorable IP outcomes and materially higher total revenue). Management acknowledged measured near-term risks including continued operating expense increases, quarter-to-quarter variability, remaining net loss (though substantially improved), and early-stage adoption dynamics. They reinforced confidence in cash sufficiency to reach profitability while accelerating investments to support long-term growth.View all GB:0XOD earnings summaries0XOD Stock 12 Month Forecast
Average Price Target
$57.33
▲(39.70% Upside)
Technical Analysis
Geron
―
Arbutus Biopharma
―
Phathom Pharmaceuticals
―
Taysha Gene Therapies
―
Zenas BioPharma, Inc.
―